Member Info for TrekMadone

It was a poorly written results RNS imo. They missed opportunities to add fact to guidance and that’s what’s psd the market off. The historical stuff and huge losses are the territories of biotech’s. They could have given more guidance on the milestone payments and more on the read out timelines. I’m now confused as to what is happing is it all hands now to oncology? If so what’s the time line on the rest, oh don’t know we sacked the admin staff. Ffs get a grip set out clear concise objectives else AIM will knock 15-20% off in a blink.

All that said I’d like to think I recognise value and sub 50p is a price that I didn’t expect and now is probably the best time to buy while the BoD pull themselves from frigging lock down apathy. Yep I’m being harsh but look at the sp. the next update will be much better, hence I added today. All imo.

Trek

Only just looked in as been out today. Great news. Flipped back through the posts and main points covered. My views align with cooper, re recommend for approval = as near as approval. That means the diagnostic’s, the tolerances, the efficacy etc have all been written up and ready for final eyes before sign off. Even if there was some gap it would be go back and clarify not throw it out and start again so it’s in the bag.

The 300 customers with emphasis on the GP surgeries is interesting. It’s like a sales lead. You already got a good rapport, the customer may want more (testing) or they may not know that they want it. It’s a good hook by the business and should also lead to an increased B2B customer base.

Icing on the cake is the seller. You only get these prices against a stellar. So if you have an investment horizon of more than next weekend you should do well here when the SP plays catch up. Needless to say I added a few here today. Usual caveats.....

Trek

I got the email from the London Stock Exchange free alerts at 07:41 this morning but was playing golf early.

I’m just wondering if the have held off the face masks/PPE until the patent was lodged...

Note these characteristics....

“The Company's Planar Thermal Circuit® is thermally conductive, electrically conductive and antibacterial. In common with all Directa Plus's products, it is produced sustainably using no chemicals and is hypo-allergenic and non-toxic.”

Now if you put that into PPE I wonder just how much additional protection and comfort that will afford over normal uncomfortable, hot, polyester workwear. I am sure there is now an appetite to be a little bit more scientific around what our front line nursing and medical staff wear.

So much news due...

Trek

I’ve just paid 42.92, sure I know it’s high for us lth’s but one cannot always control when funds become available relative to the sp. I try not to make the mistake of avoiding to pay what looks likes more but in fact all that matters is what you sell for. No FOMO for me, got the cash stuck it in . Looks like we have momentum with us now. Nice.

Trek

Membrane surfactants and protein binding: good news/bad news
Every nitrocellulose membrane on the market contains a surfactant, usually an anionic surfactant. The exact nature of the surfactant is proprietary for every membrane manufacturer, but the surfactant functions are always the same. First, it makes the membrane hydrophilic. Second, and perhaps even more important, it helps proteins bind to the membrane (Fig 4).

The good news: The surfactant partially denatures proteins dispensed onto the membrane in a buffer and helps them bind to NC fibers.

The bad news: The surfactant denatures proteins. This can potentially destroy the antigen binding sites of some monoclonal antibodies completely, making these reagents unusable in a lateral flow test.

Worth reading both links...

But AS is confident, they would have tested it on membranes before send to Cytiva for diagnostics and FDA submission

Trek

It’s not clear yet. They bind using antibodies or antigens.....sona are using antigens...and they can’t upscale consistently or rapidly.

Process...

“A lateral flow immunoassay, or immunochromatographic assay, is a rapid, convenient test that uses antibodies (or sometimes antigens) to detect specific macromolecules, such as antigens, drug substances, or other proteins.

One of the first steps in lateral flow rapid test development is the selection of the “right” materials, especially the nitrocellulose (NC) membrane. The NC is the heart of the lateral flow test, where the target molecule is bound and where the results are displayed.

A successful lateral flow immunoassay depends on a series of reactions. When selecting materials for immunoassay development, membrane properties and reagent properties must be considered together, as their interactions determine the outcome of test development.”

Full article..(note membrane is key)

https://www.cytivalifesciences.com/en/us/solutions/lab-filtration/knowledge-center/Considerations-for-membrane-selection-for-lateral-flow-immunoassays

the “Company”) is pleased to provide the following update on the development of its rapid-response, Covid-19 antigen test. The Company received confirmation from an independent laboratory that its test achieved a positive response to a recombinant whole spike protein control reagent specific to SARS-CoV2 and matched the limit of detection (LOD) achieved in its own labs. In-house analytical testing has indicated a very high level of specificity to COVID-19, with no false positives being generated.

https://sonanano.com/sona-nanotech-provides-covid-19-antigen-test-progress-update/

Ok here’s why it’s not in the bag....

Further testing will be conducted both in-house and independently using pre-treated viral samples after recent independent testing using virus samples that were de-activated by heat did not provide a response. Exposing a virus to high heat levels can modify its characteristics, making the treated virus sample an inappropriate proxy for a live sample. These findings, coupled with previous hospital-based experiments, have suggested that testing using a live viral culture and/or patient sampling will be required for ultimate confirmation of the effectiveness of the Sona test. The Company expects to confirm further third party validation testing, specific to its device needs, in the near future.

So issues with heat and stability, hence need to move to lab. They basically say between lines you need pcr type test to be sure..

Also from first link, this may also be key to avacta....Cytiva have 3 types of membrane but we don’t know yet if the Affimer is more or less susceptible to binding than the antigen on site. I would suspect that because we can bind to the whole and the detached spike protein that would mean greater sensitivity for Affimer. A guess though....

Next post

Oh I have so many! But I guess one that should go up nicely this week as they are due to deliver data from Cascadura well is TXP, now 40p expect a quid by Christmas. Fully funded and a top CEO.

Another a disruptive tech play is DCTA, a US multi-billionaire, Patrick Shoon-Shion, known as the world’s richest doctor has bought 28 % of the company. News soon on graphene in ppe, antibacterial and news with tarmac. They have trials on roads in US, Oxford and M25 and airport runways in Italy, It lasts 250% longer, fills potholes, uses existing tarmac just mix in. No need to go to quarry. Loads of other stuff. Gonna be massive growth story.

DCTA 80p (google price wrong due to spread)

Trek

The timing of the tweet is interesting. The content that they tweeted is nothing new. It’s been on the website for ages. Why cut and paste it into a tweet just now is the question.

An RNS tomorrow to say they have selected a compatible membrane for affimer LFT from their existing product range would indeed blow the doors off the SP!

So perhaps when/if that RNS lands Cytiva have just lined up a little marketing pr to coincide. All guess work.

Trek

“ Directa Plus not intending to let the coronavirus pandemic stall its progress
Cash and cash equivalents at the end of 2019 rose to €10.91mln from €5.50mln a year earlier, giving the company plenty of liquidity to ride out the disruption caused by the pandemic...”

https://www.proactiveinvestors.co.uk/companies/news/920118/directa-plus-not-intending-to-let-the-coronavirus-pandemic-stall-its-progress-920118.html

Trek

“ Hi trek
Excuse my ignorance what is a poison pill ?”

It is a condition(s) listed in the articles of association to protect a company from an unwanted approach. It could be say a share split, so the stock doubles, a minimum premium over the vwap prior to takeover Etc. Some “streetwise” companies insert terms to protect themselves from a lowball offer.

Trek

“What is the likelihood that ii's and fund managers will accept a lowball offer if there was ever a hostile takeover. Surely they will be more likely than PI's to accept, or is there a chance they may realise more could be made by holding out?“

Don’t matter it’s down to 51% of vote. Also need to read AoA’s to see if there is a poison pill.

https://www.burges-salmon.com/news-and-insight/publications/guide-to-public-takeovers-in-the-uk/#stakebuilding

Trek

They have a contract with US Dept if defence (dod) that will likely lead to more contracts.

Trek

Yes I saw the cross coming but I have made lots of trades here. Some better than others.

Trek

Thinking loud, anyone know if one test strip can pick up either or strains of a mutated virus. My guess is yes as you could have two different affimers on a test strip, but then why not just have two different strips. We’ll costs, convenience etc. The ability to knock up an affimer in 4 weeks for another strain of the virus is also a USP for this technology. If the Sun is correct it could unfortunately be needed...

“A CORONAVIRUS expert fears a mystery new outbreak hitting China is a mutant strain of the deadly bug that leaves sufferers sick for even longer.

Worryingly, the strain is behaving differently in patients in northeast China where five million people across two cities are virtually sealed off following spiralling new infections........”

https://www.thesun.co.uk/news/11675374/new-coronavirus-outbreak-china-mutant-strain/

Trek

Fk me itsyou, I reckon you are cool all year round but it’s all credit to your Mrs, not wishing to stereotype, but I’ve got you down for the ‘great smell of brut’ and a realisation that lockdown has many advantages

Hi Nolupus,

Contrarian or not you sit in the same category as the rest of us. We are all here to make a few bob. Contrarian’s, shorters, LTH’s, investors, day traders. It matters not. Amongst all the rhetoric, ramping and deramping, I hope that if grounded people get a windfall they put a little aside to do a little good. Now that’s nice! and as for mr Contrarian I see through your hard arsed posts and I bet you like me have a list of people or causes that you are gonna help. And do you know what, that for me is actually the most exciting, fulfilling part of investing now helping others.

GBU.

Trek

Oops 394 should be 494, there fat fingers rule ok! Lol!

Trek

Yes I know I have been ridiculed for purporting the benefits of basic charting knowledge as part of one’s investment toolbox. But hey I did pragmatically (well i’d like to think so) articulate the benefits of using charts in a period vacuous of news. You may recall my buy sell tolerances either side of the 20day MA.

My trades have proved rather successful, just following the channel completely agnostic of sentiment. Please note though that my safety net is if I get stuck with the shares I’m cool with that as I just add them to my core holding at 30p.

This makes a big difference in terms of risk, it’s not bread and butter, I have basically added shares at nil cost to my core holding. Ok my average is now higher and my last trade a buy at just under 54p is now looking rather dubious. You see the thing is with charts, ‘everyone’ listens when it’s going their way but the channel has now dipped below the 20DMA which is bearish.

So I should not have made that last buy! Idiot! It was a clear exit at 60p which was my sell. I caught that intraday spike a beauty and then got greedy thinking it would come again but talking in chart voodoo it is not gonna happen without news so now I am theoretically stuck holding the baby waiting for more news!

A case of not following one’s own advice, doh! But hey I traded a round 10k shares and now have an extra 394 shares after all costs and a fking headache! Lol!

I guess it pays if you have a much bigger pot but tbh I was probably lucky. I figured no news in that period, I also couldn’t care less if I was on the wrong side of a trade, i’d Just hold. So as far as I am concerned in this instance a phase three trial double blind against a buy and hold placebo the active intervention showed sufficient statistical differentiation to be given EUA for trading purposes with the usual caveats.

Here’s the chart...

https://www.marketscreener.com/SYNAIRGEN-PLC-4004905/charts/#

Trek

Could someone please post the full story.

Thanks

Trek

We sure do gettingpoorer, I have been here well of 2 years now. Maybe 3. I just keep checking my research and looking at the potential markets. It’s been a bit like going through clinical trials. Just now though we are at the primary endpoints when deals are done and royalties arrive. Iterchima was a big deal, they will do more deals. There are decent deals in the apparel space and revenues are coming through. PPE could be massive.

If I have concerns it’s setcar, whilst good in terms of proof of concept and route to market it needs a bigger scale. Like I have said before they could do with a re-think about how they market Grafysorber. Putting everything through setcar is not realising it’s maximum potential. I think that will change soon.

I think Nant has a part to play in the Directa story by helping scale up and that could be a massive SP inflection point as I don’t get buying 28% of a companies stock and not becoming actively engaged in developing its prospects unless of course you are just going to buy it out.

Trek